Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;29(5):1327-1356.
doi: 10.1212/CON.0000000000001289.

Guillain-Barré Syndrome

Ali A Habib, Waqar Waheed

Guillain-Barré Syndrome

Ali A Habib et al. Continuum (Minneap Minn). .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] Continuum (Minneap Minn). 2023 Dec 1;29(6):1921-1922. doi: 10.1212/CON.0000000000001397. Continuum (Minneap Minn). 2023. PMID: 38085906 No abstract available.

Abstract

Objective: This article summarizes the clinical features, diagnostic criteria, differential diagnosis, pathogenesis, and prognosis of Guillain-Barré syndrome (GBS), with insights into the current and future diagnostic and therapeutic interventions for this neuromuscular syndrome.

Latest developments: GBS is an acute, inflammatory, immune-mediated polyradiculoneuropathy that encompasses many clinical variants and divergent pathogenic mechanisms that lead to axonal, demyelinating, or mixed findings on electrodiagnostic studies. The type of antecedent infection, the development of pathogenic cross-reactive antibodies via molecular mimicry, and the location of the target gangliosides affect the subtype and severity of the illness. The data from the International GBS Outcome Study have highlighted regional variances, provided new and internationally validated prognosis tools that are beneficial for counseling, and introduced a platform for discussion of GBS-related open questions. New research has been undertaken, including research on novel diagnostic and therapeutic biomarkers, which may lead to new therapies.

Essential points: GBS is among the most frequent life-threatening neuromuscular emergencies in the world. At least 20% of patients with GBS have a poor prognosis and significant residual deficits despite receiving available treatments. Research is ongoing to further understand the pathogenesis of the disorder, find new biomarkers, and develop more effective and specific treatments.

PubMed Disclaimer

References

    1. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain J Neurol 2018;141(10):2866–2877. doi:10.1093/brain/awy232 - DOI
    1. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet Lond Engl 2021;397(10280):1214–1228. doi:10.1016/S0140-6736(21)00517-1 - DOI
    1. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51(4):1110–1115. doi:10.1212/wnl.51.4.1110 - DOI
    1. Koike H, Chiba A, Katsuno M. Emerging infection, vaccination, and Guillain-Barré syndrome: a review. Neurol Ther 2021;10(2):523–537. doi:10.1007/s40120-021-00261-4 - DOI
    1. Dutta D, Debnath M, Nagappa M, et al. Antecedent infections in Guillain-Barré syndrome patients from south India. J Peripher Nerv Syst JPNS 2021;26(3):298–306. doi:10.1111/jns.12459 - DOI

LinkOut - more resources